Alpha Thalassemia Market Research Report - Forecast till 2027

Alpha Thalassemia Market research report: by type (hb bart syndrome, hbh disease, silent carrier state, and trait.), by diagnosis (perinatal testing, prenatal testing, and pre-implantation), Treatment, End user -forecast till 2027

ID: MRFR/LS/3712-HCR | February 2021 | Region: Global | 90 pages

Alpha Thalassemia Market Scenario


Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin. A person is required to inherit a total of four genes to produce alpha globin protein, two of these genes are inherited from the parents. This blood disorder is caused due to abnormality or mutation in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene from parents then the person becomes a carrier of thalassemia. Since thalassemia is an inherited disorder; one of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and beta thalassemia.


Alpha thalassemia is a blood disorder that reduces the production of hemoglobin. Hb Bart syndrome is the most commonly occurring type which is characterized by hydrops fetalis, a condition in which excess fluid builds up in the body before birth.


Globally, thalassemia affects approximately 7% of the population out of which its alpha type affects 3% with many of them being transfusion-dependent patients. The alpha thalassemia market is likely to be driven by the growing market of bone marrow transplant and blood transfusion therapy, supported by high numbers of transfusion-dependent patients. Key trends in alpha thalassemia market include progressing drug pipeline, rising scope of gene therapy and growing awareness towards thalassemia. However, there are some factors which can hinder the growth of the market including regulatory changes, associated risks and the high cost of treatment.


The alpha thalassemia market is expected to grow at a CAGR of approximately 8.8% during the forecast period 2017-2023.


Key Players


Some of key the players in the alpha thalassemia market are GlaxoSmithKline Plc, Celgene, Bellicum Pharmaceuticals, Lonza group, Acceleron Pharma, BlueBird Bio, Sangamo Biosciences.


The other prominent players include Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Calimmune Inc, CRISPR Therapeutics, Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics Inc and Zydus Cadila Healthcare Ltd.


Intended Audience



  • Alpha thalassemia drug Suppliers

  • Alpha thalassemia drug Manufacturers

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The alpha thalassemia is segmented on the basis of type, diagnosis, treatment, and end-users.


On the basis of the type, the alpha thalassemia market is segmented into hemoglobin Bart hydrops fetalis syndrome or Hb Bart syndrome (the more severe form), HbH disease, silent carrier state, and trait.


On the basis of the diagnosis, the alpha thalassemia market is segmented into perinatal testing, prenatal testing, and pre-implantation. Further, the perinatal testing sub-categorized into complete blood count (CBC) And DNA testing. The prenatal testing further sub-segment into prenatal genetic testing and chorionic villus sampling. 


On the basis of the treatment, the alpha thalassemia market is segmented into blood transfusions, iron chelation, bone marrow, or stem cell transplant, surgery and gene therapy.


On the basis of the end-user, the alpha thalassemia market is segmented into hospitals, biotechnological laboratories, diagnostic laboratories, educational research institutes, pharmaceutical industries and others.


Regional Analysis


The alpha thalassemia market consists of regions namely Americas, Europe, Asia Pacific, the Middle East and Africa


North America is projected to hold the largest share of the alpha thalassemia market due to the presence of superior research and development base, strong regional economies, and greater emphasis on disease prevention and wellness by the governments. The U.S. is expected to be the first region to start selling thalassemia drugs due to developing drug pipeline and later on, alpha thalassemia market penetration of thalassemia drugs would occur in Europe. North America and Europe have a high prevalence of severe forms of alpha-thalassemia which would result in a high demand for thalassemia drugs in future.


The tropical regions are more prone to possess high numbers of patients with alpha thalassemia like Nigeria, Sudan, Chad, Columbia etc. followed by few South Asian countries. Research Institutes and Pharmaceutical companies, growing usage for alpha thalassemia testing and technological advancements, rising awareness are few factors driving alpha thalassemia market growth in the region. Few Asian countries like Myanmar and Thailand also have a high number of alpha thalassemia patients.


The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of the respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific. The alpha thalassemia market is expected to grow in future with the mounting prevalence of thalassemia, rising Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell therapy research.


The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.


Alpha Thalassemia Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology
Alpha Thalassemia Market

Sources: Annual reports, Press release, White paper, and Company presentation


The report for Alpha Thalassemia Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.8% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Calimmune Inc, CRISPR Therapeutics, Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics Inc and Zydus Cadila Healthcare Ltd.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising healthcare expenditure
  • Rising spending on stem cell therapy research
  • Development and rising population


  • Frequently Asked Questions (FAQ) :


    The alpha thalassemia market is projected to grow at an 8.8% CAGR between 2017-2023.

    North America is projected to dominate the alpha thalassemia market.

    Different end users of the alpha thalassemia market include pharmaceutical industries, educational research institutes, diagnostic laboratories, biotechnological laboratories, hospitals, and others.

    Growing awareness about thalassemia and progressing drug pipeline are the key factors driving the alpha thalassemia market growth.

    High treatment cost, associated risks, and regulatory changes may limit the alpha thalassemia market growth.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Alpha Thalassemia Market, By Type

    6.1 Introduction

    6.2 Hb Bart syndrome

    6.2.1 Market Estimates & Forecast, 2020 – 2023

    6.3 HbH disease

    6.3.1 Market Estimates & Forecast, 2020 – 2023

    6.4 Silent carrier state

    6.4.1 Market Estimates & Forecast, 2020 – 2023

    6.5 Trait

    6.5.1 Market Estimates & Forecast, 2020 – 2023

    Chapter 7. Global Alpha Thalassemia Market, By Diagnosis

    7.1 Introduction

    7.2 Perinatal testing

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.2.2 Complete blood count (CBC)

    7.2.2.1 Market Estimates & Forecast, 2020-2027

    7.2.3 DNA testing

    7.2.3.1 Market Estimates & Forecast, 2020-2027

    7.3 Prenatal testing

    7.3.1 Market Estimates & Forecast, 2020-2027

    7.3.2 Prenatal Genetic Testing

    7.3.2.1 Market Estimates & Forecast, 2020-2027

    7.3.3 Chorionic Villus sampling

    7.3.3.1 Market Estimates & Forecast, 2020-2027

    7.4 Pre-implantation

    7.4.1 Market Estimates & Forecast, 2020-2027

    Chapter 8. Global Alpha Thalassemia Market, By Treatment

    8.1 Introduction

    8.2 Blood transfusions

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 Iron chelation

    8.3.1 Market Estimates & Forecast, 2020-2027

    8.4 Bone marrow, or stem cell transplant

    8.4.1 Market Estimates & Forecast, 2020-2027

    8.5 Surgery

    8.5.1 Market Estimates & Forecast, 2020-2027

    8.6 Gene therapy

    8.6.1 Market Estimates & Forecast, 2020-2027

    Chapter 9. Global Alpha Thalassemia Market, By End User

    9.1 Introduction

    9.2 Hospitals

    9.2.1 Market Estimates & Forecast, 2020-2027

    9.3 Biotechnological laboratories

    9.3.1 Market Estimates & Forecast, 2020-2027

    9.4 Diagnostic laboratories

    9.4.1 Market Estimates & Forecast, 2020-2027

    9.5 Educational research institutes

    9.5.1 Market Estimates & Forecast, 2020-2027

    9.6 Pharmaceutical industries

    9.6.1 Market Estimates & Forecast, 2020-2027

    9.7 Others

    Chapter. 10 Global Alpha Thalassemia Market, By Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic Of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Rest of the Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 GlaxoSmithKline Plc

    12.1.1 Company Overview

    12.1.2 Treatment Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Celgene Corporation

    12.2.1 Company Overview

    12.2.2 Treatment Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Bellicum Pharmaceuticals

    12.3.1 Company Overview

    12.3.2 Treatment Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Lonza group

    12.4.1 Company Overview

    12.4.2 Treatment/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Acceleron Pharma

    12.5.1 Company Overview

    12.5.2 Treatment Overview

    12.5.3 Financial Overview

    12.5.4 Key Developments

    12.6 BlueBird Bio

    12.6.1 Company Overview

    12.6.2 Treatment Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Sangamo Biosciences

    12.7.1 Overview

    12.7.2 Treatment Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Johnson & Johnson

    12.8.1 Company Overview

    12.8.2 Treatment/Business Segment Overview

    12.8.3 Financial Overview

    12.8.4 Key Development

    12.8.5 SWOT Analysis

    12.9 Merck & Co Inc.

    12.9.1 Company Overview

    12.9.2 Treatment Overview

    12.9.3 Financial Overview

    12.9.4 Key Developments

    12.10 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical Industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Alpha Thalassemia Industry Synopsis, 2020-2027

    Table 2 Alpha Thalassemia Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Alpha Thalassemia Market by Region, 2020-2027, (USD Million)

    Table 4 Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 5 Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 6 Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 7 Alpha Thalassemia Market by End Users, 2020-2027, (USD Million)

    Table 8 North America Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 9 North America Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 10 North America Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 11 North America Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    Table 12 US Alpha Thalassemia Market By Type, 2020-2027, (USD Million)

    Table 13 US Alpha Thalassemia Market By Diagnosis, 2020-2027, (USD Million)

    Table 14 US Alpha Thalassemia Market By Treatment, 2020-2027, (USD Million)

    Table 15 US Alpha Thalassemia Market By End User, 2020-2027, (USD Million)

    Table 16 Canada Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 17 Canada Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 18 Canada Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 19 Canada Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    Table 20 South America Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 21 South America Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 22 South America Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 23 South America Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    Table 24 Europe Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 25 Europe Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 26 Europe Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 27 Europe Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    Table 28 Western Europe Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 29 Western Europe Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 30 Western Europe Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 31 Western Europe Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    Table 32 Eastern Europe Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 33 Eastern Europe Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 34 Eastern Europe Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 35 Eastern Europe Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    Table 36 Asia Pacific Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 37 Asia Pacific Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 38 Asia Pacific Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 39 Asia Pacific Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    Table 40 The Middle East & Africa Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

    Table 41 The Middle East & Africa Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

    Table 42 The Middle East & Africa Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

    Table 43 The Middle East & Africa Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Alpha Thalassemia Market

    Figure 3 Segmentation Market Dynamics for Alpha Thalassemia Market

    Figure 4 Global Alpha Thalassemia Market Share, By Type 2020

    Figure 5 Global Alpha Thalassemia Market Share, By Diagnosis 2020

    Figure 6 Global Alpha Thalassemia Market Share, By Treatment, 2020

    Figure 9 Global Alpha Thalassemia Market Share, By End Users, 2020

    Figure 10 Global Alpha Thalassemia Market Share, By Region, 2020

    Figure 11 North America Alpha Thalassemia Market Share, By Country, 2020

    Figure 12 Europe Alpha Thalassemia Market Share, By Country, 2020

    Figure 13 Asia Pacific Alpha Thalassemia Market Share, By Country, 2020

    Figure 14 the Middle East & Africa Alpha Thalassemia Market Share, By Country, 2020

    Figure 15 Global Alpha Thalassemia Market: Company Share Analysis, 2020 (%)

    Figure 16 GlaxoSmithKline Plc: Key Financials

    Figure 17 GlaxoSmithKline Plc: Segmental Revenue

    Figure 18 GlaxoSmithKline Plc: Geographical Revenue

    Figure 19 Celgene Corporation: Key Financials

    Figure 20 Celgene Corporation: Segmental Revenue

    Figure 21 Celgene Corporation: Geographical Revenue

    Figure 22 Bellicum Pharmaceuticals: Key Financials

    Figure 23 Bellicum Pharmaceuticals: Segmental Revenue

    Figure 24 Bellicum Pharmaceuticals: Geographical Revenue

    Figure 25 Lonza group: Key Financials

    Figure 26 Lonza group: Segmental Revenue

    Figure 27 Lonza group: Geographical Revenue

    Figure 28 Acceleron Pharma: Key Financials

    Figure 29 Acceleron Pharma: Segmental Revenue

    Figure 30 Acceleron Pharma: Geographical Revenue

    Figure 32 BlueBird Bio: Key Financials

    Figure 33 BlueBird Bio: Segmental Revenue

    Figure 34 BlueBird Bio: Geographical Revenue

    Figure 35 Sangamo Biosciences: Key Financials

    Figure 36 Sangamo Biosciences: Segmental Revenue

    Figure 37 Sangamo Biosciences: Geographical Revenue

    Figure 38 Johnson & Johnson: Key Financials

    Figure 39 Johnson & Johnson: Segmental Revenue

    Figure 40 Johnson & Johnson: Geographical Revenue

    Figure 41 Merck & Co Inc.: Key Financials

    Figure 42 Merck & Co Inc.: Segmental Revenue

    Figure 43 Merck & Co Inc.: Geographical Revenue